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Abstract
Aims/hypothesis Diagnosing MODY is difficult. To date,
selection for molecular genetic testing for MODY has used
discrete cut-offs of limited clinical characteristics with vary-
ing sensitivity and specificity. We aimed to use multiple,
weighted, clinical criteria to determine an individual’s
probability of having MODY, as a crucial tool for rational
genetic testing.
Methods We developed prediction models using logistic
regression on data from 1,191 patients with MODY (n0594),
type 1 diabetes (n0278) and type 2 diabetes (n0319). Model
performance was assessed by receiver operating characteristic
(ROC) curves, cross-validation and validation in a further
350 patients.
Results The models defined an overall probability of
MODY using a weighted combination of the most discrim-
inative characteristics. For MODY, compared with type 1
diabetes, these were: lower HbA1c, parent with diabetes,
female sex and older age at diagnosis. MODY was discrim-
inated from type 2 diabetes by: lower BMI, younger age at
diagnosis, female sex, lower HbA1c, parent with diabetes,
and not being treated with oral hypoglycaemic agents or insu-
lin. Both models showed excellent discrimination (c-statistic0
0.95 and 0.98, respectively), low rates of cross-validated mis-
classification (9.2% and 5.3%), and good performance on the
external test dataset (c-statistic00.95 and 0.94). Using
the optimal cut-offs, the probability models improved
the sensitivity (91% vs 72%) and specificity (94% vs 91%)
for identifying MODY compared with standard criteria of
diagnosis <25 years and an affected parent. The models are
now available online at www.diabetesgenes.org.
Conclusions/interpretation We have developed clinical pre-
diction models that calculate an individual’s probability of
having MODY. This allows an improved and more rational
approach to determine who should have molecular genetic
testing.
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Background
MODY is a rare monogenic form of diabetes [1, 2]. Mutations
in at least seven genes have been identified to date as causing
MODY, with HNF1A, HNF4A and GCK accounting for ap-
proximately 94% of cases [3]. A correct diagnosis of MODY
has implications for patient treatment: hepatocyte nuclear fac-
tor 1-α (HNF1A) and hepatocyte nuclear factor 4-α (HNF4A)
MODYare very sensitive to sulfonylurea tablets [4, 5] whereas
patients with glucokinase (GCK) MODY rarely require
pharmacological treatment [6, 7]. In addition, a diagnosis of
MODY predicts disease prognosis and identifies risk of dia-
betes in family members. It is estimated that more than 80% of
individuals with MODY in the UK are currently undiagnosed,
or misdiagnosed with type 1 or young-onset type 2 diabetes [3]
and, consequently, inappropriately treated, often with insulin.
Genetic testing is expensive, so careful consideration is
required when determining which patients should be tested.
In young-onset patients, type 1 diabetes is the most preva-
lent form, accounting for around 74% of cases in those
diagnosed under 35 (E. Pearson and R. McAlpine, personal
communication). Type 2 diabetes is less common in young
patients, but its likelihood increases with age and obesity.
MODY is rare, with estimates of its prevalence between
0.3% and 2.4% of diabetes cases [3, 8–11], although it is
recognised that these figures represent underestimates.
MODY is characterised by young age at diagnosis, strong
family history of diabetes (due to autosomal dominant inheri-
tance), and no insulin dependence [1, 2, 12]. Most clinical
criteria for defining MODY have used absolute cut-offs (e.g.
non-obese, age at diagnosis <25 years), rather than determin-
ing a probability based on continuous quantitative traits such as
BMI or age at diagnosis. Criteria based on absolute cut-offs
have shown poor sensitivity, picking up approximately only
half of patients with MODY [3, 13]. Current guidelines for
genetic testing are based on expert knowledge obtained from
clinical observation [14], but not all of the characteristics
described are routinely collected, and the likelihood of a
positive diagnosis based on these clinical features, either sepa-
rately or in combination, has not been quantified. Identifying a
way of combining simple clinical criteria in a weightedmanner,
to produce a probability of MODY, would be a valuable aid in
determining whether to test an individual for MODY.
Medical diagnostic decision models provide a way of
determining a person’s probability of having a particular
condition based on their clinical characteristics. Widely used
models such as the Amsterdam criteria and Bethesda guide-
lines for hereditary non-polyposis colorectal cancer [15] and
the Well’s score for deep vein thrombosis [16] provide
practical screening tools for selecting patients for diagnostic
testing. A clinical prediction model that generates a probability
of MODY would aid clinicians in identifying patients that are
most likely to benefit from genetic testing.
We aimed to produce a clinical prediction model for
patients with young-onset diabetes (diagnosed ≤35 years)
that uses clinical criteria to determine a patient’s probability
of having MODY compared with the more common type 1
and type 2 diabetes. This can then be turned into a simple
web-based algorithm for use by clinicians, patients and the
molecular genetics diagnostic laboratory.
Methods
Participants and data
All participants were diagnosed between the ages of 1 and
35. Type 1 diabetes was defined as occurring in patients
treated with insulin within 6 months of diagnosis [17];
otherwise patients were defined as having type 2 diabetes.
MODY patients were identified based on a confirmed
genetic diagnosis of HNF1A, HNF4A or GCK MODY.
Initial dataset
We identified 278 patients with type 1 diabetes criteria and
319 patients with type 2 diabetes criteria from five research
databases (see electronic supplementary materials (ESM)
Methods 1). These were compared with 594 probands with
a genetic diagnosis of MODY (243 GCK, 296 HNF1A and
55 HNF4A) obtained from referrals to the Molecular
Genetics Laboratory at the Royal Devon and Exeter NHS
Foundation Trust, UK. Of the MODY probands, 177 (30%)
were treated with insulin within 6 months of diagnosis and
417 (70%) were not, indicating the proportions of patients
who were likely to have been misdiagnosed as having type 1
or type 2 diabetes at referral.
A core dataset comprising key variables common to all
databases was established including sex, age at diabetes
diagnosis, age at recruitment/referral, BMI, initial and cur-
rent treatment (diet, oral hypoglycaemic agents [OHAs] or
insulin), time to insulin treatment, HbA1c and parent affected
with diabetes. As well as including the original reported BMI,
for initial exploratory analysis, BMI in children was converted
to the equivalent value in adults using the Child Growth
Foundation reference standards [18] to enable direct compari-
son between adults and children. All patients were of white
European origin. In the MODY cases, data were taken from
the referrals database, thus reflecting the patient characteristics
at referral and not following a genetic diagnosis.
Statistical approaches used for the discrimination models
Type 1 and type 2 diabetes are mutually exclusive subtypes
according to the definitions used. Therefore, only two-way
comparisons were considered: type 1 diabetes vs MODY
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and type 2 diabetes vs MODY. Three statistical approaches
were used to produce the models: logistic regression, dis-
criminant analysis and classification trees (CART). Further
details are provided in ESM Methods 2.
Discriminative ability of the models
From the logistic regression and linear discriminant analysis,
fitted probabilities were obtained from the data. Receiver
operating characteristic (ROC) curves were plotted to deter-
mine the best cut-offs in terms of sensitivity and specificity,
and the AUC (c-statistic) was used as a measure of overall
performance. For classification trees, model performance was
assessed by misclassification rates.
Validation
Jack-knife cross-validation was used on all models as a
measure of internal validation. Following completion of
the clinical model using the initial dataset, a further 350
patients were identified as a result of ongoing research
recruitment/referral: 219 with MODY, of which 83 were
probands and 136 were unrelated family members of pro-
bands used in the original model, plus a further 90 patients
with type 1 diabetes and 41 patients with type 2 diabetes
taken from community-based research cohorts (see ESM
Methods 1). This served as an external test dataset.
Post-test probabilities of MODY
The pre-test probabilities for MODY were estimated as
0.7% and 4.6% for the type 1 diabetes vs MODY and
type 2 diabetes vs MODY models, respectively (see
ESM Methods 3 for derivation). Likelihood ratios for MODY
were calculated using the sensitivity and specificity obtained
from various cut-offs in fitted probabilities in the models.
Post-test odds for MODY were obtained by multiplying the
pre-test odds by the likelihood ratio, which could then be
converted to post-test probabilities (positive predictive values).
Results
Patient characteristics (Fig. 1)
Parental history of diabetes was more common in MODY
patients (90% had at least one parent affected vs 61% in type 2
diabetes and 19% in type 1 diabetes) (Fig. 1). The 10% of
MODY cases without a parent affected is most likely to reflect
cases where the parent has undiagnosed diabetes at referral or,
in a minority of cases, where the mutation is de novo.
Patients with GCK MODY were more likely to be trea-
ted with diet alone (78%), whereas HNF1A/4A MODY
and type 2 diabetic patients were most likely to be treated with
OHAs and/or insulin (83% and 91%, respectively). By defini-
tion, all patients with type 1 diabetes were treated with insulin.
There was a higher proportion of female patients in the MODY
groups (65% in GCK MODY, 72% in HNF1A/4A MODY,
53% in type 1 diabetes, 50% in type 2 diabetes).
Figure 1 shows density plots of the continuous character-
istics of the four subtypes of diabetes. Type 2 diabetic
patients were diagnosed at an older age compared with the
other three types of diabetes (mean 30.7 vs 16.8 years,
p<0.001). Patients with type 1 diabetes had the highest HbA1c
(mean 9.1% (76 mmol/mol) vs 7.4% (57 mmol/mol) in other
types of diabetes, p<0.001), reflecting poorer glycaemic con-
trol. Type 2 diabetic patients tended to be more obese com-
pared with the other three subtypes of diabetes (mean BMI
[children adjusted to adult values] 33.1 vs 25.1 kg/m2, respec-
tively, p<0.0001).
Type 2 diabetes vs MODY models for patients who are not
treated with insulin within 6 months of diagnosis
The best model for discriminating type 2 diabetes from
MODY was found using logistic regression. Further details
of the analysis are provided in ESM Results 1. Table 1
shows the characteristics and associated beta-coefficients
and ORs from this model. The strongest predictor of MODY
was age at diagnosis, with younger patients being more
likely to have MODY (OR for MODY 0.73, [95% CI
0.68, 0.78] for every year increase in age at diagnosis).
Other variables associated with higher odds of MODY were
being slimmer (as reflected by BMI), having a parent affect-
ed with diabetes, not being treated with insulin or OHAs,
having better glycaemic control (as reflected by HbA1c),
female sex and current age (see Table 1: T2D vs MODY
model). It made little difference whether unadjusted BMI, or
BMI with child values converted to the adult equivalent,
was entered into the model. For ease of use in practice,
unadjusted BMI was chosen in the final model.
Figure 2a shows a boxplot of the fitted probabilities for
MODY from this logistic regression model for both the
MODYand type 2 diabetic patients. The majority of patients
with type 2 diabetes have low predicted probabilities for
MODY, and the majority of MODY patients have high pre-
dicted probabilities. The c-statistic (Fig. 2b) was 0.98, indi-
cating that the model showed excellent discrimination
between MODY and type 2 diabetes. Table 2 shows the
sensitivities, specificities and corresponding likelihood ratios
for MODY using different probability cut-offs in the model.
The probability cut-off maximising both sensitivity (92%) and
specificity (95%) was found to be 60% (Table 2: T2D vs
MODY model).
The model worked well when comparing type 2 diabetes
with HNF1A/4A and GCK MODY separately (ROC AUC0
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0.974 and 0.990, respectively). We also examined the sub-
group of patients diagnosed between 25 and 35 years with
HNF1A/4A MODY, as this is the most difficult group to
identify, and found that the model still worked well in
separating HNF1A/4A MODY patients from those with
type 2 diabetes (ROC AUC00.915).
Validation The prediction error from jack-knife cross-
validation was 5%, suggesting that approximately 95% of
cases would be correctly classified given this model. In the
external test dataset, the model performed well, with a
c-statistic of 0.94. A 60% probability cut-off provided
93% specificity and 87% sensitivity for MODY.
Fig. 1 Patient characteristics.
Bar plots showing percentages
of (a) parent affected by
diabetes (in black) and (b)
treatment (diet, white; OHA,
black; insulin [± OHA], grey).
Density plots for (c) age at
diagnosis, (d) HbA1c and
(e) BMI (with child values
converted to adult equivalent).
Distributions for the four
subtypes of diabetes; type 1,
solid black line; type 2, dashed
line; GCK MODY, dotted line;
HNF1A/4A MODY, solid grey
line. To convert values for
HbA1c in % into mmol/mol,
subtract 2.15 and multiply
by 10.929
Table 1 Clinical discriminators in a) type 2 diabetes (T2D) vs MODY and b) type 1 diabetes (T1D) vs MODY logistic regression models
Model Log OR (β) SE (β) z p value OR (exp[β]) 95% CI OR
T2D vs MODY model
Age at diagnosis (years) −0.32 0.03 −9.27 <0.0001 0.73 0.68, 0.78
BMI (kg/m2) −0.23 0.03 −7.29 <0.0001 0.79 0.74, 0.84
HbA1c (%)
a −0.63 0.13 −4.89 <0.0001 0.53 0.41, 0.68
Parent diabetic 1.74 0.42 4.21 <0.0001 5.74 2.61, 13.37
Age (years) −0.04 0.01 −2.64 0.008 0.97 0.94, 0.99
Insulin or OHA treated −1.0 0.44 −2.26 0.024 0.37 0.15, 0.87
Sex (male01, female02) 0.69 0.34 2.05 0.04 2.00 1.03, 3.93
T1D vs MODY model
Parent diabetic 3.14 0.34 9.12 <0.0001 23.11 12.10, 46.91
Age (years) −0.08 0.01 −6.86 <0.0001 0.92 0.90, 0.94
HbA1c (%)
b −0.66 0.10 −6.31 <0.0001 0.52 0.42, 0.63
Age at diagnosis (years) 0.10 0.02 4.25 <0.0001 1.11 1.06, 1.16
Sex (male01, female02) 1.31 0.35 3.71 0.0002 3.72 1.89, 7.61
Log OR(β), logistic regression β coefficients (log odds ratio for one unit increase in the explanatory variable)
SE(β), standard error for the β coefficient
z, standardised effect size
OR, odds ratio for one unit increase in the explanatory variable (exponential of β)
95% CI OR, 95% confidence interval for the odds ratio
a Equivalent effect sizes for HbA1c in mmol/mol: β(SE)0−0.06 (0.01); OR (95% CI)00.94 (0.92, 0.97)
b Equivalent effect sizes for HbA1c in mmol/mol: β(SE)0−0.06 (0.01); OR (95% CI)00.94 (0.92, 0.96)
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Type 1 diabetes vs MODY models for patients who
are treated with insulin within 6 months of diagnosis
The best model for discriminating type 1 diabetes from
MODY was also found using logistic regression. Further
details of the analysis are provided in ESM Results 1. The
strongest predictor of MODY in this model was having a
parent with diabetes, with those with at least one parent
affected having odds of MODY approximately 23 times
higher (95% CI 12.1, 46.9) than those without a parent
affected. Other significant predictors of MODY were lower
HbA1c, female sex, older age at diagnosis and current age
(see Table 1: T1D vs MODY model).
The model showed good performance with type 1 diabetic
patients having low predicted probabilities, and the majority
of MODY patients having high predicted probabilities for
MODY (Fig. 2c). The c-statistic was 0.95 (Fig. 2d). The
sensitivities, specificities and corresponding likelihood ratios
for MODY using different probability cut-offs in the model
are shown in Table 2. The probability cut-off maximising both
sensitivity (87%) and specificity (88%) in this model was
found to be 40% (Table 2: T1D vs MODY model).
The model worked well when considering type 1 diabetes
with HNF1A/4A and GCK MODY separately (ROC AUC0
0.934 and 0.976, respectively), and when comparing
HNF1A/4A MODY with type 1 diabetes in only those
diagnosed between 25 and 35 years (ROC AUC00.952).
Validation The prediction error from jack-knife cross-
validation was 9.2%, suggesting that approximately 90%
of cases would be correctly classified. In the external test
dataset, the model performed well, with an ROC AUC of
0.95. A 40% probability cut-off provided 93% specificity
and 82% sensitivity for MODY.
Comparison with traditional MODY criteria
Standard criteria for MODY (age at diagnosis <25 years and
parent affected with diabetes) were specific, correctly ex-
cluding MODY in 543/597 (91%) type 1 diabetes or type 2
diabetes cases, but had lower sensitivity, picking up only
425/594 (72%) MODY cases. Using the optimal cut-offs
identified, the prediction models were more sensitive at
picking up proven MODY cases (539/594 [91% sensitivity]),
with similar specificity (560/597 [94%]), correctly classifying
more patients overall (92% vs 81%, p<0.0001).
Alternative models
The best linear discriminant and classification tree models
are described in the ESM (ESM Results 2, ESM Table 1 and
ESM Figure 1).
Positive predictive values (post-test probabilities) for MODY
The positive predictive values and negative predictive values
for MODY, adjusting for prior probabilities of 0.7% and 4.6%
(for the type 1 diabetes and type 2 diabetes comparisons,
respectively) are presented in Table 2.
Compared with the type 2 diabetes vs MODY model the
positive predictive values obtained in the type 1 diabetes vs
MODY model were more modest, reflecting the lower prior
probabilities.
Online clinical prediction calculator
The equations obtained from both logistic regression models
were used to produce a web-based version of the models now
available at www.diabetesgenes.org. The clinical features of a
particular patient diagnosed ≤35 years can be entered into this
online form. For patients who are treated with insulin within
6 months of diagnosis, the type 1 diabetes vs MODYequation
will be applied to their clinical features, otherwise the type 2
diabetes vs MODYequation will be applied, and the positive
predictive value for MODY calculated.
Discussion
We have presented models showing excellent discrimination
between MODY and both type 1 and type 2 diabetes in
Fig. 2 a Boxplot of fitted probabilities for MODY from the type 2
diabetes vs MODY logistic regression model and (b) ROC curve
showing the discriminative ability of the type 2 diabetes vs MODY
logistic regression model; c-statistic00.98. Similar plots (c, d) are
shown for the type 1 diabetes vs MODY model; c-statistic00.95
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patients diagnosed ≤35 years, with c-statistics >0.94 in both
training and test datasets, and cross-validated prediction errors
of <10%. The models show considerable improvement in
prediction of MODY compared with traditional clinical cri-
teria. The models are validated, and provide post-test proba-
bilities for MODY that would be helpful in clinical practice,
particularly as supported by an online calculator. Probabilities
are produced, rather than classifications, allowing decisions
regarding testing to vary in light of other information.
Genetic testing is highly specific and sensitive and repre-
sents the gold standard for diagnosing MODY. However, the
cost limits its use in all individuals. The decision onwhether to
test is a clinical judgement that depends on the likelihood and
impact of a positive result, weighted against the expense of the
test. The current pick-up rate based on UK referrals in the
Exeter genetics diagnostic laboratory is 27% [3], which is
based on pre-selection of patients by healthcare professionals
in line with best-practice guidelines [14]. We would advise
that this model should be used in all patients diagnosed with
diabetes under the age of 35. In patients who are not treated
with insulin within 6 months of diagnosis, post-test probabil-
ities of >25% would be appropriate to trigger genetic testing.
In patients who are treated with insulin within 6 months of
diagnosis, a lower post-test probability of >10% could be
considered appropriate as the impact of finding a mutation is
greater than for a non-insulin-treated patient, both financially,
through saved treatment costs, and in terms of improved
quality of life. In these cases, further testing of C-peptide
and pancreatic autoantibodies could be carried out prior to
genetic testing, with a positive C-peptide and negative auto-
antibody result being strongly suggestive of MODY com-
pared with type 1 diabetes [19, 20]. As the cost of genetic
testing decreases, the threshold at which to refer patients will
lower. A full health-economic model would be required to
formally explore the relative trade-offs.
The pre-test probability of MODY we used is likely to be
an underestimate, particularly in the paediatric age group. In a
study of white non-insulin-treated patients under 17, it was
proposed that the probability of MODY was similar to that of
type 2 diabetes [21], much higher than 4.6% as used in our
study. In all studies to date, prevalence estimates have been
restricted by initial selection on clinical criteria before genetic
testing, and the proportion of patients missed has not been
quantified. Small increases in pre-test probabilities could
make a considerable difference to the post-test probabilities.
We have provided internal and external validation of the
model, but further testing is needed. The model should be
validated in different settings and populations, particularly
as our dataset comprised solely white Europeans. The per-
formance of the model in other populations could vary
considerably as the incidence of type 2 diabetes in adoles-
cents and young adults is more common in high-risk ethnic
groups [22]. Further validation on a community-based
population cohort would remove the biases associated with
being referred to the diagnostic service, and would elucidate
whether the female predominance is genuine.
We cannot exclude the possibility that patients in the type 1
diabetes or type 2 diabetes groups did not have MODY, as
genetic testing was not carried out on them all. It is also
possible that a few of the confirmed MODY patients may
also have coincidental type 1 or type 2 diabetes. These
misclassified patients will be a tiny minority of cases and
would have little impact on the final model.
As genetic testing becomes cheaper, its use in diagnosis
will be more commonplace. One consequence of this will be
that more variants will be identified with greater uncertainty
as to whether they are pathogenic mutations or rare poly-
morphisms of no clinical significance. Probability models
based on clinical criteria, such as those presented here, may
then have a different but equally important role in producing
prior probabilities for MODY to inform the likelihood of
pathogenicity of a novel mutation.
Incorporating other characteristics into the model could
improve its diagnostic ability. Only basic clinical characteristics
were used in these models and data were limited to information
available for all participants. Some important clinical features
known to be indicative of MODY, type 1 diabetes and type 2
diabetes were not included. Pancreatic autoantibodies [23] and
measures of endogenous insulin secretion, such as persistent
C-peptide [24], are highly sensitive and specific biomarkers of
type 1 diabetes, which have been shown to discriminate well
between MODY and type 1 diabetes [19, 20]. Young-onset
type 2 diabetes is more common in non-white populations and
is often characterised by signs of insulin resistance, such as
acanthosis nigricans [22], which is rare in MODY. HNF1A
MODYpatients show sensitivity to sulfonylureas [4, 5], have a
low renal threshold for glucose [25], and lower high-sensitivity
C-reactive protein (hsCRP) levels [13]. A small glucose incre-
ment in an OGTT is predictive of a diagnosis of GCK MODY
[26]. Information on these additional factors is not always
collected. The advantage of the clinical criteria we have used
is that it should be routinely available for all patients. We have
already shown excellent discrimination (ROC AUC>0.94)
using clinical characteristics alone. The next important step
will be to assess the additional value of other biomarkers,
which would be most useful in aiding decisions in insulin-
treated patients. Provided that they are independent, it is possi-
ble to account for other information by combining likelihood
ratios for any additional test with that produced by the model.
In conclusion, we have produced a clinical prediction
model that shows good discrimination between MODY
and the more common type 1 diabetes and type 2 diabetes
in patients diagnosed under the age of 35. This should
provide a useful aid for selecting patients for diagnostic
genetic testing for MODY who may benefit from improved
treatment and management if a mutation is identified.
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